AstraZeneca Readies New Portfolio of Targeted Cancer Therapies

MADRID— is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.

Through its alliance with Japan’s Daiichi Sankyo, AstraZeneca has been at the forefront of the latest generation of a class of medicines known as antibody-drug conjugates, or ADCs, which aim to replace standard chemotherapy by striking tumors directly with a toxic agent. But the U.K. drugmaker is now developing an in-house lineup.